Smithkline Beecham Corporation

Lubrizol Genetics, Inc.

Human Genome Sciences, Inc.

Other

Glaxosmithkline LLC

Mycogen Plant Science, Inc.

Edward Robert Appelbaum

Richard M Cook

Robert S Ames

Irwin M Chaiken

Stephen Dudley Holmes

Mitchell Stuart Gross

Lynette Jane McMillan

Timothy Wayne Theisen

John Richard White

Mark D Adams

Haodong Li

Ralph Froman Alderson

David M Parmelee

Yuling Li

Henrik S Olsen

Solange H L Gentz

Henry M Sarau

Hauke Hennecke

Solange Hanschke Lima

Joseph W Lamb

Michael Gottfert

Renee Kosslak

Roger Bookland

Solange H Gentz

Eric Johansen

Michael P O'Connell

Thomas J McLoughlin

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Antibodies to MCP-4

Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Human chemokine beta-10 mutant polypeptides

Antibodies to human CK&bgr;-10/MCP-4

Disclosed are methods for discovering agonists and antagonists of the interaction between a secreted human protein, chemokine CK.beta.-9, and its cellular receptor, human CCR7, which may have utility in the treatment of several human diseases, including, but not limited to: allergic disorders, autoimmune diseases, ischemia/reperfusion injury, development of atherosclerotic plaques, cancer (including mobilization of hematopoietic stem cells for use in chemotherapy or mycloprotection during chemotherapy), chronic inflammatory disorders, chronic rejection of transplanted organs or tissue grafts, chronic myelogenous leukemia, and infection by HIV and other pathogens.

Methods of screening for agonists and antagonists for human CCR7

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated

The present invention relates to treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs and other altered antibodies such as Fabs, chimeric, human and humanized antibodies that do not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor.

Method for treatment and diagnosis of IL-5 mediated disorders

DNA encoding chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5

Methods for the isolation of mutant rhizobial strains with improved competition of nodulation (Comp.sup.+) is presented. Mutants are selected for constitutive expression of inducible nod genes (in the absence of inducer) and screened for hyperinduction of nod genes in the presence of inducer. Mutants which are defective in nodulation or in symbiotic nitrogen fixation are eliminated from further testing. Selections for constitutive nod expression and for hyperinduction of nod genes are facilitated by the use of plasmid carrying a selectable marker fused to an inducible nod gene and a plasmid carrying a reporter gene fused downstream of an inducible nod gene. The methods exemplified are particularly useful for the isolation and identification of Comp.sup.+ mutants of Bradyrhizobium japonicum.

Method for selecting mutants of legume-nodulating bacteria enhanced in

The chemical compounds that induce expression of nodulation genes of Bradyrhizobium japonicum strains have been identified. The isoflavones daidzein and genistein were identified as soybean exudate components that induce nod-genes. Other isoflavones, including 7-hydroxyisoflavone, 5,7-dihydroxyisoflavone, biochanin A, formononetin and prunetin, were also found to act as inducers. In addition, several flavonoid compounds including 4',7-dihydroxyflavone, apigenin, kaempferol and coumestrol, were also found to act as inducers. Nodulation inducing compositions and a method for selectively activating the expression of a gene under the control of a soybean exudate inducible promoter in B. japonicum in response to these inducer molecules are described. In addition, soybean inoculating compositions containing the nod-gene inducers and inoculating methods employing these compositions are described.

Bradyrhizobium japonicum nodulation inducing factor

Growing community of inventors

Blue Bell, PA, United States of America

Edward Robert Appelbaum